60 Degrees Pharmaceuticals
SXTP | NASDAQ
$0.49
-$0.03 (-5.39%)
At close: Nov 16, 2026, 4:00 PM ET
$0.51
+$0.02 (+4.35%)
After-hours:
Nov 16, 2026, 7:33 PM ET
-5.39%
(1D)No price chart data available for 1D timeframe.
Rating
38.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #578/1021 (Top 57%)
Key Statistics
Market Data
Market Cap $1.74M
1D Range
0.46 0.51
52W Range
0.46 5.20
Valuation (TTM)
PE -0.08
PB 0.66
EV/EBITDA -0.11
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $13.85
Cash Flow
FCF Yield -515.4%
SBC Adj. FCF Yield -521.8%
SBC Impact -1.3%
Margins
Gross Margin 19.4%
Operating Margin -774.9%
FCF Margin -805.6%
Growth (CAGR)
Revenue 3Y | 5Y 87.2% |
-14.3%
Dil EPS 3Y | 5Y 5.0% |
-45.1%
FCF 3Y | 5Y -18.0% |
-45.4%
Returns
ROA -189.4%
ROE -211.6%
ROIC -321.2%
Financial Health
Net Cash
$871.43K
Current Ratio 2.32
Interest Coverage -1,134.85
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United Stat...
Sector Healthcare
Industry Biotechnology
Employees 3
IPO Date Jul 12, 2023
Website www.60degreespharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 16, 2026
EPS
-$0.75
Miss -22.95%
YoY:
+71.59% REV
$233.24K
Miss -13.62%
YoY:
-53.35%Next Earnings
Mar 26, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$13.85
Upside
+2726.53%
Buy (1)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove SXTP